Literature DB >> 29097811

Therapy: Biosimilars in rheumatology - why, how and when in 2017.

Roy Fleischmann1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29097811     DOI： 10.1038/nrrheum.2017.179

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  6 in total

Review 1.  Biosimilars: implications for rheumatoid arthritis therapy.

Authors:  Stanley Cohen; Jonathan Kay
Journal:  Curr Opin Rheumatol       Date:  2017-05       Impact factor: 5.006

2.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

Review 3.  Use of biologics in rheumatoid arthritis: current and emerging paradigms of care.

Authors:  Jeffrey R Curtis; Jasvinder A Singh
Journal:  Clin Ther       Date:  2011-06       Impact factor: 3.393

4.  Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.

Authors:  Jonathan Kay; Monika M Schoels; Thomas Dörner; Paul Emery; Tore K Kvien; Josef S Smolen; Ferdinand C Breedveld
Journal:  Ann Rheum Dis       Date:  2017-09-02       Impact factor: 19.103

Review 5.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Authors:  Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon
Journal:  Arthritis Rheumatol       Date:  2015-11-06       Impact factor: 10.995

6.  Letter--Draft FDA Guidance "Considerations in Demonstrating Interchangeability with a Reference Product": Overview and Presentation-Related Concerns.

Authors:  Elan Rubinstein
Journal:  J Manag Care Spec Pharm       Date:  2017-03
  6 in total
  2 in total

Review 1.  An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.

Authors:  Xin Zhou; Zhuo Chen; Xinling Bi
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162

2.  Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.

Authors:  Syed Numan; Freddy Faccin
Journal:  Adv Ther       Date:  2018-08-06       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.